Target intelligence / Profile preview

FXYD domain containing ion transport regulator 4 (FXYD4)

Target
FXYD4
Molecular classification
Ion channel regulator, Auxiliary subunit of the sodium/potassium-transporting ATPase (Na,K-ATPase), Small transmembrane protein, Member of the FXYD protein family
01

Overview

FXYD domain containing ion transport regulator 4 (FXYD4) is a small transmembrane protein and auxiliary subunit of the Na,K-ATPase. It belongs to the FXYD family, sharing a conserved 35-amino acid signature domain. FXYD4 modulates Na,K-ATPase by altering its affinity for Na+ and enhancing pump activity, fine-tuning sodium and potassium transport across membranes in a tissue-specific manner. This activity is crucial in tissues such as the kidney, where it regulates sodium reabsorption and electrolyte balance. Abnormal expression or function of FXYD4 has been linked to genetic disorders (e.g., hypomagnesemia, deafness) and is downregulated in some cancers, notably clear cell renal cell carcinoma, making it of interest both as a therapeutic target and a disease biomarker[1][2][3][4][6].

Other names
Channel-inducing factor (CHIF)FXYD4_HUMAN (Uniprot designation)Corticosteroid hormone-induced factor (may refer to its expression regulation)
02

Mechanism of action

Modulation of Na,K-ATPase activity (would alter sodium/potassium transport, affecting cell and tissue electrolyte balance). Drugs or hormones that regulate FXYD4 expression may indirectly impact ion transport and homeostasis.

03

Biological functions

Fine-tuning of ion transport (especially sodium and potassium ions)Regulation of Na,K-ATPase activity (affinity for Na+, enzyme stability)Maintenance of cellular electrolyte balanceCritical for kidney sodium reabsorptionModulation of epithelial transport (e.g., in uterus for implantation)
04

Disease associations

Hypomagnesemia 2, renalDeafness, autosomal recessive 33Renal malignancy (clear cell renal cell carcinoma; diagnostic/prognostic marker potential)Possible implication in multiple cancers (breast, lung, prostate, urothelial, colon)
05

Safety considerations

Targeting ion transport regulators such as FXYD4 may risk electrolyte imbalance, affecting cardiac, neural, and renal functionsOff-target effects could include disturbances in Na+ and K+ levels, leading to arrhythmia or muscular dysfunction
06

Interacting drugs

Corticosteroids
07

Biomarkers

Downregulation in clear cell renal cell carcinoma suggests use as a biomarker for renal malignancyExpression in renal, uterine, and epithelial tissues might serve as biomarkers for function or disease involvement

Beyond the preview

Go deeper on FXYD domain containing ion transport regulator 4 (FXYD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FXYD domain containing ion transport regulator 4 (FXYD4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call